Search company, investor...
Brandenburg company logo


Founded Year



Acquired | Acquired

About Brandenburg

Brandenburg is a manufacturer of flying and biting insect control systems.On January 13th, 2022, Brandenburg was acquired by Pelsis. The terms of the transaction were not disclosed.

Headquarters Location

29 Navigation Drive, Hurst Business Park, Brierley Hill

West Midlands, England, DY5 1UT,

United Kingdom

Missing: Brandenburg's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Brandenburg's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Brandenburg Patents

Brandenburg has filed 1 patent.

The 3 most popular patent topics include:

  • Organic gardening
  • Entomology equipment
  • Sustainable agriculture
patents chart

Application Date

Grant Date


Related Topics




Capacitors, Computer memory, Wireless networking, Electromagnetism, Electricity


Application Date


Grant Date



Related Topics

Capacitors, Computer memory, Wireless networking, Electromagnetism, Electricity



Latest Brandenburg News

Tech company continues expansion with manufacturing acquisition

Jan 14, 2022

Brandenburg acquired by Pelsis Group Growing global pest control technology company Pelsis Group has completed its first acquisition of 2022 with the purchase of Brandenburg, a leading manufacturer of flying and biting insect control systems, for an undisclosed sum. The deal, which is the second in two months for Knaresborough headquartered firm, following the acquisition of Spanish businesses Sanitrade and Vesta Distribuciones and supports the firm’s growth strategy described by the CEO as “adding companies that are leaders in their category”. Following the acquisition, Brandenburg which is based near Dudley but also has a facility in Saint Charles, Missouri and a manufacturing plant in the Pune region of India, is now a wholly owned subsidiary of Pelsis, meaning the business has a turnover approaching €200m and employs more than 700 people across 18 sites located throughout Western Europe, the US and India. Pelsis Group CEO, Derek Whitworth The news of the new acquisition comes as the technology group also announced Derek Whitworth had been appointed interim CEO replacing Andrew Milner. Whitworth who was previously CEO of TMD Fricton a tier one supplier to the automotive sector and executive chairman of automotive remanufacturer BBB Industries from 2014 to 2017, said of that Brandenburg shares similar goals, values and aspirations for the future as Pelsis. He added: “We see great potential for ongoing growth opportunities and there are many clear benefits of working together that will provide customers with enhanced levels of product innovation, service and support.” Brandenburg founder and chief executive, Mathew Kaye, said: “It has been a long and rewarding journey to have built Brandenburg into the company it is today. “We feel that our business is ready for the next stage in its journey. Joining the Pelsis Group presents a great opportunity for deep collaboration and further investment in product innovation. Ultimately, it improves our ability to grow and develop our business to serve our customers even better. We are very excited about the future.” Jan-Derck van Karnebeek Pelsis has also confirmed the appointment of Jan-Derck van Karnebeek as the company’s interim chief commercial officer. He is a 19-year veteran of The Heineken Company, culminating in six years as the global CCO. Pelsis chairman, Martin Schwab, said: “I am very pleased to welcome Derek and Jan-Derck to Pelsis and look forward to accelerating the development of the company as a major international player in the global pest control industry. “The Board of Pelsis would like to thank Andrew Milner for his impressive work in building the company since he joined in 2019.” Pelsis was advised on the legal and financial aspects of the Brandenburg acquisition by DLA Piper and EY respectively. Previous Article

Brandenburg Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Brandenburg Rank

Brandenburg Frequently Asked Questions (FAQ)

  • When was Brandenburg founded?

    Brandenburg was founded in 1948.

  • Where is Brandenburg's headquarters?

    Brandenburg's headquarters is located at 29 Navigation Drive,, West Midlands.

  • What is Brandenburg's latest funding round?

    Brandenburg's latest funding round is Acquired.

  • Who are the investors of Brandenburg?

    Investors of Brandenburg include Pelsis and Midven.

  • Who are Brandenburg's competitors?

    Competitors of Brandenburg include Molmed, Pronucleotein, Advanced Analytical Technologies, Calibrant Biosystems, ARCXIS and 11 more.

Compare Brandenburg to Competitors


Inscentinel Ltd is a biotechnology company specializing in harnessing the olfactory ability of insects for trace vapor detection. The company's primary focus is the development of handheld portable detectors, through the use of live honeybees. This Inscentinel Technology offers sensitive vapour detection coupled with distinct operational advantages.

Bug Power

Bug Power is a biotech company planning to produce a talented strain of bacteria that can simultaneously clean up waste, eliminate odor and generate electricity in portable toilets. The company's first product is the eToilet which aims to be an eco-friendly, electricity generating toilet that uses waste to power fans, lights and sensors that make portable toilets cleaner, brighter and odorless.


CellXplore is a new, biotechnology company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer. Although mammography is an effective screening test for early detection, there is a need for a simple, reliable and sensitive biomarker-based in vitro assay that can be used to stage and characterize breast cancer.nThe company was formed to commercialize groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions.nCellXplore's platform technology is not restricted to breast cancer in vitro diagnostics alone, nor is it restricted to cancer diagnostics alone. Beyond cancer, CellXplore is already investigating whether similar blood sample biomarkers can be identified for the early diagnosis of several major debilitating diseases such as muscle wasting, Alzheimer's disease, Parkinson's disease and inflammatory diseases.

CELLective Dx Corporation

CELLective Dx is an early-stage company developing a new generation of diagnostic tools for cancer based on analysis of CTCs directly from a patient's blood. Our novel proprietary technologies combine microfluidics, flow dynamics, cell biology, molecular biology, biochemistry, and surface chemistry to capture and analyze rare CTCs in blood more rapidly and effectively than other current technologies. CELLective Dx is developing simple, rapid, blood-based cancer tests that will provide physicians and patients with accurate and individualized clinical information on disease status, treatment selection, and treatment response that will dramatically improve the clinical management of cancer.

MOgene LC

MOgene is a biotechnology company, focused on understanding the mechanisms of cellular and organismal toxicity of chemical compounds and applying the knowledge to improve safety and efficacy of products across life science industries. MOgene uses a systems biology approach to understand gene function in the context of biological networks, to develop assays and biomarkers for molecular diagnostic solutions that would help address toxicity issues. MOgene is an Agilent-certified gene expression service provider and aims to provide microarray services including custom design of arrays, experiment design and detailed bioinformatics analysis.


Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.